Luminex Co. (NASDAQ:LMNX) announced a quarterly dividend on Thursday, December 14th, Wall Street Journal reports. Stockholders of record on Friday, December 22nd will be paid a dividend of 0.06 per share by the medical instruments supplier on Friday, January 12th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Thursday, December 21st.
Shares of Luminex (NASDAQ LMNX) traded up $0.13 during trading on Thursday, hitting $20.52. The stock had a trading volume of 552,400 shares, compared to its average volume of 199,882. The company has a market capitalization of $898.27, a price-to-earnings ratio of 35.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.19. Luminex has a 12 month low of $17.68 and a 12 month high of $22.42.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. The company had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. Luminex had a return on equity of 6.01% and a net margin of 9.52%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.21 earnings per share. equities analysts forecast that Luminex will post 0.49 earnings per share for the current year.
LMNX has been the topic of a number of research reports. TheStreet upgraded Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Zacks Investment Research upgraded Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 price target on the stock in a report on Thursday, August 24th. Jefferies Group restated a “hold” rating and issued a $21.00 price target on shares of Luminex in a report on Friday, October 20th. ValuEngine raised Luminex from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Finally, BidaskClub downgraded Luminex from a “hold” rating to a “sell” rating in a research report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.00.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.